Dr David Gilligan

Qualifications

BSc (Hons), MB BChir, FRCP (Edin), FRCR, MA

GMC number: 3122095

Practising since: 1985

Specialties

Clinical Oncology

Consultation times

  • Weekly Monday 17:00 - 20:00
  • Overview
Enquire now

Or call us on

01223 370 922

About

David Gilligan is a Consultant Oncologist in the Thoracic Oncology Unit at Addenbrooke's and Papworth Hospitals in Cambridge. He is also a recognised clinical teacher at the University of Cambridge School of Clinical Medicine. He trained in Oncology at The Christie Hospital, Manchester and in London at The Royal Marsden Hospital and University College Hospitals.

David Gilligan is a Consultant Oncologist in the Thoracic Oncology Unit at Addenbrooke's and Royal Papworth Hospitals in Cambridge. He is also an Affiliated Assistant Professor at the University of Cambridge School of Clinical Medicine. He trained in Oncology at The Christie Hospital Manchester and in London at The Royal Marsden Hospital and University College Hospitals.

Dr Gilligan has been a member of the NCRI Lung Cancer Studies Group and was a member of Council, Royal College of Radiologists. He is a Senior Medical Editor for Macmillan. He sits on the Steering Committee of the British Thoracic Oncology Group (BTOG).

His main clinical and research interests are in all aspects of thoracic oncology and cancer of unknown primary. 

Dr Gilligan treats patients with chemotherapy including targeted therapy and immunotherapy. If required he will arrange and supervise radiotherapy at a separate location.

Special interests

Thoracic oncology (lung cancer and mesothelioma)
Cancers of unknown primary origin.

Other interests

Recent publications include:

The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton, Peter Fletcher,, Sanjay Popat , Joshua Savage, Yvonne Summer , Alastair Greystoke,  David Gilligan, Judith Cave, Noelle O'Rourke, Alison Brewster, Elizabeth Toy, James Spicer, Pooja Jain, Adam Dangoor, Melanie Mackean , Martin Forste , Amanda Farle , Dee Wherton, Manita Mehm , Rowena Sharp, Tara C Mills , Maria Antonietta Cerone , Timothy A Yap , Thomas B K Watkins, Emilia Lim , Charles Swanton, Lucinda Billingham
Nature. 2020 Jul;583(7818):807-812.  doi: 10.1038/s41586-020-2481-8.  Epub 2020 Jul 15.

Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma
Noorani A, Li X, Goddard M, Crawte J, Alexandrov LB, Secrier , Eldridge, Bower L, Weaver J, Lao-Sirieix P, Martincorena I, Debiram-Beecham I, Grehan N, MacRae S, Malhotra S, Miremadi A, Thomas T, Galbraith S, Petersen L, Preston SD, Gilligan D, Hindmarsh A, Hardwick RH, Stratton MR, Wedge DC, Fitzgerald RC.
Nature Genetics. 2020 Jan;52(1):74-83. doi: 10.1038/s41588-019-0551-3. Epub 2020 Jan 6

Lung cancer in never-smokers: a hidden disease.
Bhopal A, Peake MD, Gilligan D, Cosford P.
J R Soc Med. 2019 Jul;112(7):269-271. doi: 10.1177/0141076819843654. Epub 2019 Apr 25

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Tan CS, Gilligan, D & Pacey, S.
Lancet  Oncology (2015) Sep;16(9):e447-59. doi: 10.1016/S1470-2045(15)00246-6.

Acute Oncology: A bona fide subspecialty or a distraction from the day job?
Gilligan D
Clinical Oncology (2014) 26: 128-9 (Editorial)

Preoperative chemotherapy in patients with resectable non-small cell lung cancer: Results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of sytematic review. 
Gilligan D , Nicholson M, Smith I, Greon H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, Smit h, van Meerbeeck H, Nankivell M, Parmar M, Pugh C and Stephens R.
Lancet(2007) 369: 1929-37

Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. 
Lee SM, James L, Qian W, Spiro S, Eisen T, Gower N, Ferry D, Gilligan D, Harper P, Prendiville J, Hocking M and Rudd R.
Thorax (2008) Sep 11 [Epub ahead of print]

Paraneoplatic limbic encephalitis attributable to thymoma 
Chaudhray MS, Waters M, and Gilligan D
Journal of Thoracic Oncology (2007) 2:879-80

Adjuvant chemotherapy in non-small cell lung cancer - how feasible is it in a non-trial population
Treece SJ, Magee L, Gilligan D and Harden SV 
Clinical Oncology (2007) 19:629-30

Early compared with late radiotherapy in combined modality treatment for limited disease small cell lung cancer:  a London Lung Cancer Group mutlicenter trial and meta-analysis.
Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Riuz de Elvira MC, O'Donnell KM, Gower NH, Harper PG, Hackshaw AK,; London Lung Cancer Group
Journal of Clinical Oncology (2006) 24:3823-530

Treatments and tests offered by Dr David Gilligan at Nuffield Health

  • Chemotherapy

Locations Dr David Gilligan works with

Related experience

Memberships

  • Royal College of Radiologists
  • British Thoracic Oncology Group
  • International Association for Study of Lung Cancer
  • Fellow of the Royal College of Physicians of Edinburgh (FRCPE)
  • Member of the NHS England Lung Cancer Expert Group
  • Member of the Steering Committee of the British Thoracic Oncology Group (BTOG)
  • Medical and Dental Defence Union Scotland (MDDUS)

Other posts held

  • Consultant, Addenbrooke's NHS Trust Hospital Cambridge and Papworth Hospital Cambridgeshire

Declaration

Dr David Gilligan does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.

Dr David Gilligan does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.

Dr David Gilligan does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.